This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Business / Merck & Co. Gardasil sales lawsuit
Business class action lawsuit

Merck & Co. Gardasil sales lawsuit

Analysis based on 47 articles · First reported Feb 12, 2025 · Last updated Apr 07, 2025

Sentiment
-50
Attention
4
Articles
47
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The class action lawsuit against Merck & Co. for alleged securities fraud regarding its Gardasil sales forecasts in China has led to a significant decline in Merck & Co.'s stock price. This event highlights the importance of transparent communication from publicly traded companies to maintain investor confidence and avoid legal repercussions.

Pharmaceuticals Legal Services
Event Summary

Merck & Co. is facing multiple class action lawsuits from law firms including Levi & Korsinsky, The Gross Law Firm, and Rosen Law Firm. The lawsuits allege that Merck & Co. misled investors about its expected revenue of $11 billion from Gardasil sales by 2030, particularly concerning demand in China. On February 4, 2025, Merck & Co. announced it would cease Gardasil shipments to China through at least midyear due to over-inflated channel inventories and lower-than-expected demand. This news caused Merck & Co.'s stock price to drop by over 9% in a single day. Shareholders who purchased Merck & Co. shares between February 3, 2022, and February 3, 2025, are encouraged to join the class action, with a lead plaintiff deadline of April 14, 2025.

Key Actions
100 Levi & Korsinsky notified investors Merck & Co.
91 Merck & Co. published Q4 2024 results
85 Merck & Co. declined
85 Rosen Law Firm filed class action lawsuit Merck & Co.
Entities Involved
stock
Merck & Co.
Merck & Co. is facing a class action lawsuit for allegedly misleading investors about the sales forecasts of its Gardasil vaccine in China, leading to a significant stock price decline.
Importance 100.0 Sentiment -70.0
oth
Gardasil
Gardasil is the product whose sales forecasts in China were allegedly misrepresented by Merck & Co., leading to the class action lawsuit.
Importance 60.0 Sentiment -50.0
per
Jiang Rensheng
Jiang Rensheng is Merck & Co.'s distributor in China, which allegedly experienced inflated inventory due to Merck & Co.'s lack of visibility into Gardasil demand.
Importance 30.0 Sentiment -10.0
govactor
United States — United States District Court for the District of New Jersey
The United States — United States District Court for the District of New Jersey is the venue where the class action lawsuit against Merck & Co. has been commenced.
Importance 30.0 Sentiment 0.0
per
Michael Francis Crotty
Michael Francis Crotty is the named plaintiff in the class action lawsuit against Merck & Co.
Importance 10.0 Sentiment 0.0
per
Joseph E. Levi
Importance 0.0 Sentiment 0.0
priv
Levi & Korsinsky
Importance 0.0 Sentiment 0.0
priv
Rosen Law Firm
Importance 0.0 Sentiment 0.0
per
Lawrence Rosen
Importance 0.0 Sentiment 0.0
per
Philip Kim
Importance 0.0 Sentiment 0.0
cnt
China
Importance 0.0 Sentiment 0.0
Relationships
United States — United States District Court for the District of New Jersey related ↔ Rosen Law Firm
United States — United States District Court for the District of New Jersey related ↔ Philip Kim
Joseph E. Levi partner ↔ Levi & Korsinsky Joseph E. Levi is an attorney and named partner at Levi & Korsinsky, where he represents investors in securities class a
Joseph E. Levi related ↔ Rosen Law Firm
Joseph E. Levi related ↔ Lawrence Rosen
Joseph E. Levi related ↔ Philip Kim
Levi & Korsinsky related ↔ Rosen Law Firm
Levi & Korsinsky related ↔ Lawrence Rosen
Levi & Korsinsky related ↔ Philip Kim
Rosen Law Firm related ↔ Lawrence Rosen
Rosen Law Firm related ↔ Philip Kim
Lawrence Rosen founding partner ↔ Philip Kim Lawrence Rosen is a founding partner of the Rosen Law Firm, where he directs attorneys including Philip Kim. Together, t
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.